GHRP-6 side effects and safety context

Short-term tolerability in the published human work was unremarkable: the original study in 18 healthy men reported "no adverse clinical effects or laboratory abnormalities" in response to GHRP-6 at any dose tested (Bowers et al., J Clin Endocrinol Metab 1990). The two things that make GHRP-6 different from the newer, more selective secretagogues are dose-dependent prolactin and cortisol release, and appetite stimulation inherent to the receptor it acts on. The broader issue is scope: that 1990 study, and short pharmacology sessions like it, are essentially the whole human safety record.

"Less selective than ipamorelin" is the standard description, and it is accurate, but the magnitude is usually left out. In the 1990 study, serum prolactin and cortisol rose about two-fold above basal levels — and did so only at the highest dose of 1.0 µg/kg, not at 0.1 or 0.3 µg/kg. LH and TSH did not change over the first hour after dosing (Bowers 1990).

Two qualifications belong beside that. The effect is dose-dependent, so the cortisol concern applies to larger stimulation doses rather than to every exposure. And it is a class property rather than an idiosyncrasy: the same axis activation is well documented for GHRP-2, where a 100 µg intravenous dose produces a cortisol response correlating with the insulin tolerance test at r = 0.817 (Kano et al., Peptides 2010). Animal work indicates the adrenal effect is indirect, mediated mainly through hypothalamic corticotropin-releasing factor rather than a direct pituitary action (Hirotani et al., Naunyn Schmiedebergs Arch Pharmacol 2005).

What nobody has published is a multi-hormone panel across weeks of repeated subcutaneous GHRP-6 in humans. Whether cortisol elevation persists, adapts, or accumulates over a cycle is unknown.

GHRP-6's reputation for producing sudden, intense hunger is consistent with its mechanism. It agonises the growth hormone secretagogue receptor, whose natural ligand is ghrelin — a stomach-derived peptide that both releases GH and drives food intake (Kojima et al., Nature 1999).

The controlled human measurement was made with GHRP-2 rather than GHRP-6: a 35.9 ± 10.9% increase in food intake at a buffet meal versus saline, with no change in what participants chose to eat, only how much (Laferrère et al., J Clin Endocrinol Metab 2005). Expect the effect; do not expect a published number attached to GHRP-6 specifically. And note the direction of the problem — for anyone using it while in a calorie deficit, this is the compound's most reliable effect working directly against the objective.

A compound that raises GH and IGF-1 inherits the concerns printed on approved growth hormone labels: glucose intolerance, fluid retention, joint pain, intracranial hypertension, and neoplasm risk. A review of growth hormone secretagogues found them generally well tolerated but singled out increases in blood glucose driven by decreased insulin sensitivity, and called explicitly for evaluation of cancer incidence and mortality with long-term use (Sigalos & Pastuszak, Sex Med Rev 2018).

The longest human dataset in this class involves a different molecule. Two years of oral MK-677 in 65 healthy older adults raised fasting glucose by about 5 mg/dL, lowered insulin sensitivity, and produced increased appetite, transient mild lower-extremity oedema and muscle pain as the commonest complaints (Nass et al., Ann Intern Med 2008). Fluid retention and joint aching track GH elevation itself and are plausible with any effective secretagogue.

Almost everything anyone would want to know about repeated GHRP-6 use is unstudied. There is no published trial of chronic subcutaneous dosing in healthy adults, no carcinogenicity study, no reproductive toxicology, and no post-marketing surveillance system covering it, because it has never been marketed as a medicine.

What class reviews do establish is that the GH-releasing effect of these peptides undergoes partial desensitisation — more during continuous infusion, less during intermittent administration — while prolonged administration still raises IGF-1 (Ghigo et al., Eur J Endocrinol 1997). Diminishing response is not itself harmful; escalating the dose in response to it moves into territory no study has examined.

A separate category of risk attaches to the product rather than the molecule. Material sold outside a pharmacy supply chain carries no verified identity, purity, aggregate or endotoxin data — the attributes that determine immunogenicity risk in an injected peptide.

GHRP-6 is prohibited in sport at all times under WADA section S2. It is largely excreted unchanged and has been detected in urine 23 hours after administration, with its metabolites detectable for about 12 (Semenistaya et al., Drug Test Anal 2015).

See also GHRP-6 benefits and dosing education.